|
|
|
| Effect of nasal rinse frequency on adverse reactions associated with radical radiotherapy for nasopharyngeal carcinoma |
| BAO Wenting DENG Junjian WANG Qinglan HU Jiating DENG Yangqing WU Long XU Ximing |
| Cancer Center, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
Abstract Objective To study the therapeutic effect of different nasal flushing frequency on radiotherapy related adverse reactions in patients with nasopharyngeal carcinoma. Methods A total of 108 patients received radical radiotherapy for nasopharyngeal carcinoma in the Oncology Department of Cancer Center, Renmin Hospital of Wuhan University from January 2013 to December 2016 were selected. According to the random number table method, the patients were divided into two groups, group A and group B, who received nasal irrigation with nasal cola irrigator. The frequency of irrigation in group A was 3 times/d, and the frequency of irrigation in group B was 5 times/d, and the irrigation time was from the day of radiotherapy to 1 year after the end of radiotherapy. The incidence and efficacy of mucosal reactions, pain and anxiety in the two groups were recorded. Results The incidence of mucosa reaction in group B was significantly better than that of group A, the incidence of moderate or above degree of pain and anxiety scores were lower than those of group A, the difference was statistically significant (P ＜ 0.05), However, there was no statistically significant difference in the short-term efficacy between the two groups (P > 0.05). Conclusion In patients with nasopharyngeal carcinoma receiving radical radiotherapy, nasal flushing for 5 times/d can further reduce local mucosal adverse reactions, relieve pain and anxiety, and improve patients′ treatment experience and quality of life compared with 3 times/d.
|
|
|
|
|
|
[1] Kamran SC，Riaz N，Lee N. Nasopharyngeal carcinoma [J]. Surg Oncol Clin N Am，2015，24（3）：547-561.
[2] Chen YP，Chen L，Li WF，et al. Reporting Quality of Randomized，Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma [J]. Int J Radiat Oncol Biol Phys，2017，98（1）：170-176.
[3] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018. [Epub ahead of print].
[4] Chua MLK，Wee JTS，Hui EP，et al. Nasopharyngeal carcinoma [J]. Lancet，2016，387（10 022）：1012-1024.
[5] Lin W，Yip YL，Jia L，et al. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma [J]. Nat Commun，2018，9（1）：4663.
[6] Liang SB，Zhang N，Chen DM，et al. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma [J]. Radiother Oncol，2019，132：223-229.
[7] Huang CI，Chen LF，Chang SL，et al. Accuracy of a staging system for prognosis of 5-year survival of patients with nasopharyngeal carcinoma who underwent chemoradiotherapy [J]. JAMA Otolaryngol Head Neck Surg，2017， 143（11）：1086-1091.
[8] Tang LQ，Chen DP，Guo L，et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma：an open-label，non-inferiority，randomised phase 3 trial [J]. Lancet Oncol，2018，19（4）：461-473.
[9] Sun Y，Li WF，Chen NY，et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3，multicentre，randomised controlled trial [J]. Lancet Oncol，2016，17（11）：1509-1520.
[10] Toh HC，Ha TC，Wee J. Personalised medicine in nasopharyngeal cancer [J]. Lancet Oncol，2012，13（6）：568-569.
[11] Bhattacharyya T，Babu G，Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal cancer [J]. J Oncol，2018，2018：3725837.
[12] Yao CY，Zhou GR，Wang LJ，et al. A retrospective dosimetry study of intensity-modulated radiotherapy for nasopharyngeal carcinoma：radiation-induced brainstem injury and dose-volume analysis [J]. Radiat Oncol，2018， 13（1）：194.
[13] Zhou S，Chen C，Liu SR，et al. Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy：A retrospective analysis of 830 patients stratified by the 8th edition of the UICC/AJCC staging system and plasma Epstein-Barr viral [J]. J Cancer，2018，9（18）：3352-3360.
[14] 中国鼻咽癌临床分期工作委员会，鼻咽癌1992分期修订工作报告[J].中华放射肿瘤学杂志，2009，18（1）：2-6.
[15] Cox，JD，Stetz，J，Pajak，TF. Toxicity criteria of the radiation therapy oncology group （RTOG） and the European organization for research and treatment of cancer （EORTC） [J]. Int J Radiat Oncol Biol Phys，1995，31：1341-1346.
[16] Renee SR. Pain：clinical manual for nursing practice [J]. Nurs Stand，1994，9（11）：55.
[17] Zung WW. A rating instrument for anxiety disorders [J]. Psychosomatics，1971，12（6）：371-379.
[18] Huang XD，Zhou GQ，Lv JW，et al. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era：A big-data，intelligence platform-based analysis [J]. Radiother Oncol，2018，129（2）：389-395.
[19] Liao W，Zhou H，Fan S，et al. Comparison of significant carotid stenosis for nasopharyngeal carcinoma between intensity-modulated radiotherapy and conventional two-dimensional radiotherapy [J]. Sci Rep，2018，8（1）：13899.
[20] Chen C，Fei Z，Huang C，et al. Prognostic value of tumor burden in nasopharyngeal carcinoma [J]. Cancer Manag Res，2018，10：3169-3175.
[21] 陈伊宁，宋斌，温文胜.鼻咽癌放疗后放射性鼻－鼻窦炎56例报道[J].中华放射医学与防护杂志，2005，25（1）：77.
[22] 张友梅，宦莉莉，沈腊梅，等.鼻咽癌放疗配合鼻咽冲洗及口腔护理的临床观察[J].现代中西医结合杂志，2003， 12（8）：844-845.
[23] 何林，陈松，余新文，等.鼻咽冲洗对鼻咽癌放疗效果的影响[J].右江民族医学院学报，2010，32（3）：382-383. |
|
|
|
